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ABSTRACT 
Organ transplantation prolongs thousands of lives each year. While the evolution of post-
transplant immunosuppressant therapies and better surgical techniques have improved short-term 
patient prognosis, these advancements have had little impact on long-term graft attrition and 
patient survival rates. Over-immunosuppression caused by anti-rejection therapies drugs 
increases recipient infections and cancer. Onerous, yet imprecise, surveillance procedures 
impose a burden on patients, but poorly detect nascent rejection. The identification of reliable 
biomarkers of rejection would enable earlier identification of rejection episodes and allow 
dynamic adjustment of immunosuppressant drug therapies.  Interleukin (IL)-33 is a novel IL-1 
family cytokine that is expressed or induced in several cell types (epithelial, endothelial, and 
myeloid cells, and myofibroblasts) and found in the tissues of commonly transplanted organs, 
including the heart, lungs, small bowel, and kidney.  IL-33 has pleiotropic effects on the 
leukocytes and stromal cells expressing its receptor, Growth Stimulation Gene-2 (ST2). The 
effects of IL-33 are negatively regulated by a soluble decoy receptor, soluble ST2 (sST2). 
Several studies have demonstrated that mechanical stress or inflammatory stimuli, including IL-
1β and TNFα, are able to induce both sST2 and IL-33 in cardiac myocytes and endothelial cells. 
Clinical measurements of circulating sST2 have been found it to be predictive of cardiovascular 
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disease risk and mortality in patients with a history of myocardial infarction (MI). Specifically, 
following MI, elevated sST2 indicates severe cardiac damage and predicts patient mortality. 
Increased levels of sST2 and IL-33 are observed in the sera of patients with inflammatory bowel 
disorders. Based on these reports, we hypothesized that IL-33 and ST2 expression are distinctly 
modulated in allografts due to pro-inflammatory cytokines secreted by infiltrating immune cells 
and that these proteins will serve as sensitive biomarkers of rejection. To test this hypothesis in a 
cohort of pediatric heart and small bowel transplant recipients, we examined levels of ST2/sST2 
and IL-33 both locally in the allograft tissue and systemically during periods of rejection and 
quiescence. In endomyocardial biopsies (EMB) collected from rejecting heart transplant 
recipients, we found that both ST2 and IL-33 were increased significantly (p=0.0359 and 0.0049 
respectively) compared to non-rejecting patients. Likewise, we observed similar increases in IL-
33 and ST2 in patient sera (p=0.0006; sST2 and p=0.0010; IL-33). In small bowel patients 
undergoing rejection, biopsy samples displayed upregulation of ST2 gene expression (3.94-fold 
increase over non-rejection) and analysis of collected sera revealed an increase in ST2 levels 
(p=0.0306) in these patients. Our findings provide strong evidence that ST2 and IL-33 could 
function as tissue- and most importantly, serum-based biomarkers of rejection. This discovery 
would benefit the overall public health of allograft recipients by enabling earlier transplant 
rejection diagnosis, alleviate complications due to over-immunosuppression, and decrease 
reliance on biopsy procedures.   
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1.0  INTRODUCTION 
1.1 ORGAN TRANSPLANTATION: EARLY HISTORY 
Researchers first began experimenting with organ transplantation on both animals and 
humans in the 18
th
 century. However, these procedures were plagued by surgical and immune 
complications. These barriers included functional failure of the allograft itself, infection, and 
immune-mediated destruction of the graft tissue, which was recognized as non-self, foreign 
material. Early attempts focused on the kidney and used pigs, sheep, and goats as a source of 
organs. However, none of the kidneys functioned for long, if at all, and most patients perished 
within a few hours after transplantation (1). Cadaver tissue was also a source of organs and was 
many times collected from prisoners following execution. However, even with compatible 
blood-type matching often times these poor quality grafts would only last a matter of days before 
failing (1). In Paris in 1953, Drs. Jean Hamburger and Louis Michon performed the first attempt 
at live donor kidney transplantation (mother-to-son). In the absence of immunosuppressants to 
stop destruction, or rejection of the graft tissue, the organ functioned for three weeks before 
succumbing (2).  The same procedure was completed in 1954 by Drs. Joseph E. Murray and John 
Merrill at Brigham & Women’s Hospital in Boston, Massachusetts (3).  However, this would be 
the first successful renal transplantation because the graft was a highly viable kidney from a 
living monozygotic twin.  Because the transferred kidney was genetically identical to that of the 
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recipient, the recipient immune system perceived the graft as self, and no agents were required to 
subdue immune-mediated graft rejection (3).  
During the same period, others were beginning to unravel the immunology underlying 
allograft rejection and how to thwart it. In Nobel Prize winning work, Peter Medawar 
demonstrated that graft rejection is the result of an immunological event in the early 1940s (4). 
In the early 1950s, researchers began investigating the means to suppress the immune system by 
experimenting with adrenal cortical steroids and irradiation in laboratory animals (5, 6). Both 
prolonged graft survival marginally, but not to a significant degree. However, this set the stage 
for development of drug therapy as treatment for rejection. The first evidence of prolonging of 
allograft function due to drug therapy was demonstrated in 1960, when Willard Goodwin 
produced severe bone marrow depletion in a young female who had been transplanted with her 
mother’s kidney by administering metho-trexate and cyclophosphamide (7). The patient 
subsequently developed rejection episodes attributed to recovery of bone marrow, but effects 
were temporarily reversed due to treatment with prednisone (7). Research using anti-leukemia 
drugs 6-MP and azathioprine showed promise by delaying rejection in rabbits in a dose 
dependent manner, demonstrating a mechanism of T-cell inhibition which provided better patient 
outcome than depletion a of bone marrow cells (8, 9). Over the last several decades, multiple 
classes of immunosuppressant drugs have been developed and due to emergence of these new 
therapies, prognosis following acute rejection has steadily improved.  
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1.2 ORGAN TRANSPLANTATION TODAY 
Organ transplantation has now evolved into a procedure that consistently prolongs 
survival in both adult and pediatric patients undergoing end-stage organ failure (10, 11). In 2013 
greater than 28,000 organ transplantation procedures were completed (optn.transplant.hrsa.gov). 
Currently, one year survival rates exceed 90% in kidney transplant recipients and are above 80% 
for heart, liver, lung, and intestinal allograft recipients (10). Improvements are attributed to 
advancements in surgical procedures and development of effective drug regimens. However, 
even with these improvements, barriers to successful patient outcomes still exist (12). 
1.3 CURRENT BARRIERS TO SUCCESSFUL TRANSPLANTATION OUTCOMES 
1.3.1 Acute Cellular Rejection 
Acute cellular rejection (ACR) is most common within the first six months to one year of 
transplantation (13, 14). ACR is typically asymptomatic until diagnosed by biopsy or until graft 
dysfunction presents itself, such as arrhythmias or heart palpitations in the case of heart 
transplants (14). While the cellular and molecular events that precipitate ACR are complex, it is 
most notably characterized by infiltration of mononuclear cells, typically, CD3-positive T-
lymphocytes as well as macrophages (14). ACR is observed due to the inflammation generated 
via T-cell responses directly to donor Human Leukocyte Antigens (HLAs) expressed on donor 
tissues and antigen presenting cells (APCs) in a process referred to as direct allorecognition. 
ACR can also be induced by indirect allorecognition, which occurs as a result of donor peptides 
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that are processed and then presented by recipient APCs in the context of self HLA (14, 15). This 
T-cell activity leads to their release of pro-inflammatory cytokines and cell lytic proteins, which 
can lead to tissue damage, necrosis, and graft loss of graft. The likelihood of a patient developing 
ACR increases with the number of HLA mismatches between donor and recipient, other factors 
include young age, female gender, and race (13). The current ‘gold standard’ for diagnosis of 
ACR within allografts involves biopsy of the transplanted tissue and examination by a transplant 
pathologist.  For example, cardiac allografts are assessed by routine endomyocardial biopsy 
(EMB) (13, 14, 16). EMB samples are then pathologist scored and severity is graded on a scale 
determined by the International Society for Heart and Lung Transplantation (ISHLT) (Table 1) 
(12).  A 0R grade denotes no evidence of cellular rejection while a grade of 3R is representative 
of severe ACR with diffuse cellular infiltrate, multifocal cellular damage, and vasculitis (12).  
Currently, death/graft loss due to acute rejection within the first year post-transplant is rare; 
however, episodes of ACR are common and typically can be remediated by treatment with 
immunosuppressant drugs.  
 
Table 1: International Society for Heart and Lung Transplantation Grading Scale for ACR (2005) 
 
 
Modified from Miller et al. 2013 Heart. 
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1.3.2 Antibody Mediated Rejection 
Antibody-mediated rejection (AMR) is not as easily characterized and diagnosed as ACR. 
Following heart transplantation, AMR is similar to ACR and can result in vascular damage, graft 
dysfunction and loss (13, 17). AMR occurs in about 10-20% of all heart transplant recipients and 
is associated with a higher risk of death than with ACR (13). Typically referred to as non-cellular 
or humoral rejection, AMR results from sensitization of the recipient to donor HLAs present in 
the allograft tissue (13, 17, 18). This sensitization results in the production of donor specific 
antibodies (DSA) (17). Another characteristic of AMR is complement binding, however, 
evidence now indicates the existence of a complement-independent mechanism as well (18). 
After solid organ transplantation, diagnosis of AMR is based on the detection of DSA in the 
serum and staining of the complement protein C4d in biopsied tissue.  Complement activation 
induced by DSA can lead to endothelial activation within the graft which causes a harmful 
inflammatory response that in severe cases can lead to the recruitment of innate leukocytes such 
as activated macrophages that bind to the DSAs which can lead to targeted lysis of cells in the 
surrounding microvasculature resulting in tissue damage (17). Like ACR, AMR in heart 
transplant recipients is graded on a scale created by the ISHLT (Table 2) (14). Even with these 
criteria, AMR can be challenging to diagnose as pathology between cases can vary greatly (13). 
Common treatment regimens for AMR often include plasmapheresis coupled with intravenous 
immunoglobulin (IVIg), and administration of anti B-cell agents (19, 20). 
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Table 2: International Society for Heart and Lung Transplantation Grading Scale for AMR (2011) 
 
1.3.3 Current Immunosuppressant Therapy 
Early immunosuppressants such as the ones mentioned earlier played an essential role in 
improving prognosis following transplantation. Tacrolimus is still commonly used today along 
with other therapeutic drugs such as alemtuzumab, rapamycin (sirolimus), and mycophenolate 
mofetil (MMF). These agents as well as other glucocorticoids and inhibitors work through 
various mechanisms that decrease T-cell activity and limit immune activation (12). Likewise, 
bortezomib, eculizumab, and anti-CD20 work to suppress B-cell, plasma cell, and complement 
activity associated with AMR (19, 21). Earlier methods of bone marrow depletion were found to 
be harmful and counteractive to better patient prognoses (1). While later immunosuppressant 
therapies (IST) supported improved graft attrition, hyperlipidemia, neurotoxicity, and 
diabetogenicity were all common side effects of these drugs (1). IST regimens today support 
fewer acute side effects, but their generalized suppressive function can also lead to infectious and 
malignancy related complications. Viral infections such as Epstein-Barr (EBV) which drives 
post-transplant lymphoproliferative disease (PTLD) and human cytomegalovirus (CMV) are 
Modified from Miller et al. 2013 Heart. 
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leading causes of morbidity in the immunosuppressed patient (22-24). In addition to these 
infectious complications, IST can also lead to the development of malignancies of the rectum, 
skin, and gynecological organs (12).  Over-time IST can result in cumulative effects such as: 
renal toxicity, hypertension, and decreased bone density (12). While the benefits of IST are 
undeniable, these side effects can be taxing on transplant recipients, particularly pediatric 
patients who often times face a lifetime of treatment.  
1.3.4 Diagnosis of Rejection 
As acute rejection and other complications are common within the first year of 
transplantation, patients undergo routine surveillance to monitor graft function and to assess 
overall health (13). As mentioned earlier the standard of rejection diagnosis for most types of 
organ transplants is via tissue biopsy. Sampling usually occurs weekly during the first month 
post-transplantation, every two weeks for another two months, once monthly until the sixth 
month mark, then every three months until the end of the first year or anytime rejection is 
suspected (13).  During biopsy procedures, several 1-2mm fragments of tissue are collected from 
the transplanted organ and placed in 10% formalin (25). The tissue is then embedded in paraffin, 
sectioned, and placed on glass slides. These slides are then stained and evaluated by pathologists. 
The typical histological staining of biopsied tissue is hematoxylin & eosin (H&E), which enables 
assessment of tissue and vascular architecture, and C4d staining, which evaluates AMR status 
(14, 25). Biopsies can indicate degree of tissue damage and determine the presence of 
mononuclear infiltrates, commonly T-cells and macrophages, which are indicators of ACR as 
described above. While this method is widely used it also has several shortcomings: it is costly, 
invasive, and provides a small spectrum of analysis given the small area sampled (13). In cardiac 
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transplant recipients this procedure also carries with it the risk of myocardial perforation, 
arrhythmia, access-site complications, and tricuspid regurgitation (14). In small bowel transplant 
recipients common complications are intestinal perforation and bleeding (26). The biopsy 
procedure, due to its invasive nature, is burdensome on high-risk patients who require frequent 
sampling, this often times leads to non-adherence of the patient to treatment and surveillance 
plans which could eventually result in development of rejection (27-29). 
1.3.5 A Need for Innovations in Post-Transplant Care 
Although IST is accredited with improving short-term patient outcomes, the continual 
evolution of IST has done little to improve long-term transplant recipient prognoses (10, 12).  It 
is well appreciated that even the newest IST contributes to pathological conditions suffered by 
long-term survivors, such as hypertension and cardiac allograft vasculopathy (CAV) (10, 12). 
Biopsies, while the standard of diagnosis, are invasive, uncomfortable for patients, and not well 
suited for frequent sampling (27, 28). Thus, in order to improve long-term patient survival 
significant innovations in both post-transplant therapeutics and diagnostic care are required. The 
discovery of reliable biomarkers for rejection could be key in spearheading the way to a more 
targeted approach to post-transplant care. This advancement would limit complications from 
over-immunosuppression by allowing for adjustment of IST drugs and could also decrease 
dependence on biopsy procedures. 
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1.4 INTERLEUKIN-33 (IL-33) AND GROWTH STIMULATION GENE-2 (ST2) AS 
BIOMARKERS 
1.4.1 Current Biomarkers of Rejection 
Throughout the years, several tissue-based and circulating molecules have been proposed 
as biomarkers for rejection. Currently, the most common rejection markers are indicators of 
tissue necrosis, or in the case of heart transplant rejection, myocardial necrosis. Examples 
include: creatine kinase, cardiac troponin I, and C-reactive protein (13, 30). However, even 
though these markers correlate with rejection and are prognostic of outcome, they fall short in 
that they are typically only detectable after significant damage to the allograft has already 
occurred (13). Other circulating factors currently used to support a diagnosis of rejection are 
antibodies to HLAs and complement fragments. However, many other factors have been 
investigated, such as plasma cytokine measurements of IL-8, IL-6, and TNF-α, as well as 
activation markers such as CD69, and the soluble form of CD30 (31-33). While it is true that 
many of these molecules can be upregulated during acute rejection, they have been found to be 
either non-predictive of prognosis or lacking the specificity necessary to be used as accurate 
biomarkers. This highlights the importance of continued research to identify reliable serum and 
tissue-based biomarkers of rejection (13). Such a discovery would enable quicker diagnosis of 
rejection episodes which could lead to decreased accumulation of allograft damage over time 
and improvement of long-term patient prognoses.  Likewise, the availability of a reliable early 
rejection biomarker(s) would enable dynamic regulation of IST to match current allograft 
conditions. This diagnostic capacity would reduce over immunosuppression and its related 
toxicities. 
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1.4.2 Why IL-33 and ST2? 
Since its discovery in 2005, interleukin-33 (IL-33), an IL-1 family cytokine, has been 
most commonly known for its ability to promote T helper 2 (TH2) responses and association with 
asthma and autoimmunity (34, 35). Recently, IL-33 and its receptor Growth Stimulation Gene-2 
(ST2) have emerged as indicators of cellular stress and inflammation (34, 36). In mice, it has 
been published that inflammatory stimuli, such as viral infections LCVM and influenza A, 
induce IL-33 in the lungs (37, 38). Also, the development of atherosclerosis in rodents has been 
associated with an increase in vascular tissue expression of this cytokine (39). Clinical 
measurements of the soluble form of the IL-33 receptor, sST2, have been noted to be predictive 
of mortality and cardiovascular disease risk in patients with heart failure or myocardial infarction 
(MI) (40-42). Interestingly, in cases of inflammatory bowel disorders such as Crohn’s Disease 
and ulcerative colitis, both sST2 and IL-33 are found to be increased in serum (43-45). Another 
study showed that elevated levels of sST2 at time of diagnosis of graft-versus-host disease 
(GVHD) were prognostic of treatment-resistance and death (46). Accumulating evidence in both 
clinical and experimental models support the concept that increasing expression of IL-33 and/or 
ST2 could possibly serve as quantitative indicators of pathological inflammation.  
The role of IL-33 during allograft rejection is currently unknown.  Using a murine model 
of heart transplantation (HTx), we previously published that ST2 was increased locally, but not 
systemically, in allograft tissue during acute rejection (47, 48). In a separate article, it was 
described that sST2 was elevated in the sera of adult HTx patients during ACR (49). These data 
suggests that increases in ST2 in HTx EMB and/or serum may be a sensitive indicator of HTx 
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rejection.  Also, given the observed systemic and local upregulation of IL-33 and ST2 during 
pathological inflammatory conditions of the vasculature and mucosa, it is possible that either 
factor could serve as biomarkers or sensitive indicators of rejection in allograft tissue (36).  
1.4.2.1 Immunobiology of IL-33 and ST2 
IL-33 is a recently identified member of the IL-1 family and is constitutively expressed in 
endothelium and epithelium, but can be induced in myofibroblasts and myeloid cells by  
inflammatory stimuli (34, 36). IL-33 is most commonly known for its role in asthma and 
autoimmune conditions (34, 50). IL-33 is generated as a biologically active cytokine that consists 
of a C-terminal cytokine domain, N-terminal nuclear localization sequence, and DNA binding 
domains that targets the protein to the nucleus (36). However, in contrast to other IL-1 family 
members, IL-33 is inactivated by cleavage with caspases 3 and 7 (51-53). Thus, the proteolytic 
mechanism that releases IL-33 from the nucleus for secretion is not well established.  However, 
the active full length form IL-33 is thought to be released from the nucleus through tissue 
necrosis. Released IL-33 has also been proposed to act as an “alarmin” that alerts the immune 
system to pathology (51-53) and has pleotropic effects on adaptive and innate immune cells that 
express its receptor ST2.  Specifically, by targeting leukocytes, including T cells, mast cells, 
eosinophils, basophils, innate lymphoid cells, and myeloid APC, IL-33 drives type 2 response 
dominated by IL-5 and IL-13 (35, 47, 54) Yet, IL-33 can also support immune regulation 
through the expansion of regulatory T and myeloid-derived suppressor cells (47). IL-12 induces 
ST2 on NK and CD8
+
 T cells and subsequent exposure to IL-33 augments IFN- production by 
these cells (55, 56).  
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Modified from Liu and Turnquist, 2013 Cytokine. The IL-33 cytokine contains two domains: a homeodomain-like 
helix-turn-helix domain at the N-terminus and an IL-1-like cytokine domain located at the C-terminus.  It also 
contains a nuclear localization signal and a chromatin binding motif which mediate association which histones and 
nuclear translocalization. Site where proteolytic cleavage and deactivation by caspase 3 and 7 occurs is marked by an 
X .
Figure 1: Human Interleukin-33 molecule
  
The IL-33 receptor, Growth Stimulation Gene-2 (ST2), which the literature sometimes 
denotes as IL-1 receptor-like 1 (IL1RL1), exists both as a transmembrane form and soluble 
decoy receptor, referred to as sST2.  Both proteins are generated through alternative splicing of a 
single mRNA (57, 58). ST2 is a member of the Toll-like/IL-1 receptor (R) family and utilizes the 
IL-1R accessory protein to induce NF-kB and mitogen-activated protein kinases following IL-33 
ligation (36). Both the soluble and membrane bound isoforms of this molecule are augmented in 
leukocytes and non-hematopoietic cells by inflammatory stimuli, including IL-1β, TNFα, or 
lipopolysaccharide (LPS), and well as mechanical stress (59). 
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2.0  STATEMENT OF THE PROJECT AND SPECIFIC AIMS 
 Innovation in post-transplant therapeutic care and rejection diagnostics is required as 
evolution of IST has failed to significantly improve long-term allograft survival. Currently, the 
standard for diagnosis of allograft rejection is pathologist-graded tissue biopsy, a costly and 
cumbersome methodology that is poorly suited for routine surveillance (14).  This procedure is 
particularly burdensome on high-risk pediatric patients who require frequent monitoring (27, 28). 
The identification of a reliable graft/serum-derived biomarker will improve on long-term 
outcomes by enabling earlier diagnosis and treatment of rejection.  It should also support precise 
adjustment of IST to lowest levels possible for effective rejection protection without repeated 
invasive biopsy procedures. This will be especially impactful for pediatric patients, who often 
require frequent monitoring (27, 28) and are most susceptible to the cumulative side effects of a 
lifelong IST (12). Upregulation of IL-33 and ST2 during pathological inflammatory conditions 
of suggest they could serve as biomarkers or sensitive indicators of rejection in allograft tissue 
(36). Thus, we hypothesize that expression of both IL-33 and ST2 is distinctly modulated locally 
in allografts during rejection due to pro-inflammatory cytokines. We anticipate that these 
proteins can serve as sensitive and precise biomarkers of early transplant rejection.  
To test our hypothesis we proposed two specific aims: 
1. Determine if ST2 and IL-33 are modulated locally in allograft tissue by 
inflammatory cytokines. In our rodent studies we demonstrate that IL-33 and ST2 is 
modulated in rejecting cardiac allografts. To substantiate this observation in a cohort of 
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pediatric heart transplant recipients, we utilized Quantum-dot immunolabeling (Qdot) 
coupled with Whole-Slide Imaging (WSI) to evaluate tissue expression of IL-33 and ST2 
in patient EMBs. To quantitate the data derived from these methods we utilized NearCyte 
analytical software. To examine upregulation of ST2 and IL-33 in small bowel transplant 
recipients, gene expression in intestinal biopsies received from the University of 
Nebraska was measured as part of a 384 gene qRT-PCR array. Assessment of genes and 
associated networks was completed using Ingenuity Pathway Analysis (IPA) software. 
2. Define if systemic alterations in ST2 and IL-33 levels are indicative of transplant 
rejection. To evaluate this aim, we measured levels of sST2 and IL-33 in sera collected 
from the same transplant groups described in Aim 1 using Enzyme-Linked 
Immunosorbent Assay (ELISA). Results were interpreted based on absorbance and 
compared between groups. 
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3.0  METHODS 
3.1 PRELIMINARY RODENT STUDIES 
Rodent Heterotopic Heart Transplantation: C57BL/6J (H2
b
, B6) and BALB/c (H2
d
) 
mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Mice were housed in the 
specific pathogen-free facility of the University of Pittsburgh, School of Medicine used at 8–12 
wk of age. Heterotopic (intra-abdominal) heart transplantation was performed using 
microsurgical techniques as described by Corry et al. (60) by Dr. Quan Liu of the Turnquist 
laboratory. Experiments were conducted under an institutional animal care and use committee-
approved protocol and in accordance with National Institutes of Health guidelines.  
Protein extraction and Immunoblotting: Total HTx protein lysates were generated in 
RIPA buffer supplemented with protease inhibitors. Lysates were cleared by centrifugation 
(13,000 rpm for 20 min) and the protein concentration was determined with a DC protein assay 
kit (Bio-Rad, Hercules, CA). SDS/PAGE, transfer onto PVDF membranes and 
immunodetection were performed. For primary antibodies, anti-ST2 (Ab25877; Abcam) and 
anti-GAPDH (Sigma-Aldrich, St. Louis, MO) were used as described previously (61). The 
HRP-labeled secondary antibodies were used followed by detection with SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Fisher Scientific, Watham, MA). Western blot assays for 
rodent studies were completed by Dr. Quan Liu. 
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3.2 PATIENT POPULATIONS  
Pediatric Heart Transplant Recipients:  In collaboration with Dr. Brian Feingold we 
received samples collected from among 39 patients (demographics represented in Table 3) 
enrolled in an IRB approved (IRB# 0702122), prospective study of the prevalence of 
alloantibodies after heart transplantation at Children’s Hospital of Pittsburgh of UPMC (median 
age 6.4 years). We identified acute cellular rejection (n=8 in 6 patients), antibody-mediated 
rejection (n=4 in 4 patients), and no rejection biopsies (n=13 in 11 patients) for which there was 
concurrent serum available to us for IL33/ST2 ELISA analysis. We also separately identified 
ACR events (n=7 in 4 patients), AMR events (n=7 in 5 patients), and no rejection events (n=7 in 
6 patients) for which EMB specimens were available for quantum dot analysis. For each patient 
demographic and pertinent clinical data were obtained. For both analyses, patient events were 
matched by age, sex and time after HTx. 
All patients received thymoglobulin induction therapy with subsequent tacrolimus-based 
immunosuppression plus adjunctive sirolimus or mycophenolate mofetil. Only patients with a 
positive, donor-specific cytotoxicity crossmatch or antibody-mediated rejection were treated with 
chronic steroids. All patients underwent serial post-HTx allograft surveillance EMB at 1-2 
weeks, 2-4 weeks, 2 months, 4 months, 6-7 months, and 10-12 months. Patients also underwent 
EMB if rejection was suspected and to assess resolution following the rejection treatment. 
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Table 3: Patient Demographics of Pediatric Heart Transplant Recipients 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Small Bowel Transplant Recipients: We obtained samples from 18 individuals (83% < 
18 years old) (demographics represented in Table 4) undergoing isolated small bowel or multi-
visceral transplantation from Dr. Ryan Fisher at the University of Nebraska Medical Center from 
2004 to 2009. Samples were gathered from an established, institutional review board-approved 
tissue collection bank (IRB approval #417-02). Patients and/or parents of patients who 
underwent SBTx and who are scheduled to undergo surveillance intestinal biopsy, diagnostic 
Table 1. Clinical Characteristics of Pediatric Heart Transplant Recipients
Total number of patients 39 100%
Males 23 59%
Females 16 41%
Recipient age at transplant
Mean 8.0 ±6.4
Median 7.0
Recipient age at transplant <18y 37 95%
Recipient age at transplant ≥18y 2 5%
Etiology of heart failure
Congenital heart disease (CHD) 13 33%
Cardiomyopathy (CM) 22 56%
Re-Transplantation (ReTx) 4 10%
Ave. Graft Survival (Years as of 11/18/2013) 4.88 ±1.56
T-cell crossmatch (TXM)
Negative 34 87%
Positive 2 5%
Strong Positive 3 8%
B-cell crossmatch (BXM)
Negative 9 23%
Postive 3 8%
Strong Positive 2 5%
Not Done 25 64%
Sex Matched Donor (Y) 46%
Ethnicity/Race
White 30 77%
Arabic 1 3%
White/Asian 1 3%
White/Arabic 1 3%
Black 5 13%
Hispanic 1 3%
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intestinal biopsy, or surgery involving the intestine were informed of the study.  Sample tissue 
collected included additional biopsy specimens at the time of endoscopy, and the concomitant 
collection of extra blood. The intestinal tissue specimens were stored at -80°C in RNAlater 
(Applied Biosystems/Ambion, Austin, TX).   The blood was centrifuged, and the serum stored at 
-80°C.  
 
Table 4: Patient Demographics of Pediatric Small Bowel Transplant Recipients 
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3.3 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) 
Levels of serum sST2 in transplant patients and normal controls were measured using 
commercially available ELISA kits (DuoSet, R&D Systems, Minneapolis, MN, USA). All serum 
samples were isolated at the time of collection, frozen the same day and stored at minus 80
o
C 
until use.  On the day of assessment, samples were batch thawed and determinations of IL-33 and 
sST2 completed. All samples were analyzed in triplicate according to manufacturer 
specifications. Assay limits of detection are 31.25 pg/mL (sST2) and 23.44 pg/mL (IL-33). 
Absorbance was measured utilizing a Benchmark Plus™ plate reader (Bio Rad, Hercules, CA, 
USA) at a wavelength setting of 450nm.    
3.4 QUANTUM DOT IMMUNOLABELING (Qdot) 
Paraffin embedded patient EMBs were sectioned (4 μm) onto slides, which were then 
deparaffinized, steamed with antigen retrieval buffer pH 9.0 for 30 mins, and followed by 
blocking with avidin/biotin (Vector) and Serum Free protein block (Dako). Slides were then 
labeled overnight with rabbit anti-ST2 antibody (1:30, Sigma Aldrich, St. Louis, MO) and rat 
anti-IL-33 antibody (1:30, R&D, Minneapolis, MN). On day 2, after the slides were washed 
multiple times in PBS, anti-rabbit and rat biotinylated IgG secondary antibodies (1:200) were 
added consecutively and followed by respective streptavidin conjugated Qdot® 705 (1:50, ST2) 
and 655 (1:50, IL-33) (Life-Technologies) with avidin/biotin blocking between steps. Finally, 
slides were counter-stained with Hoechst nuclear dye and dehydrated by washing two times each 
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with 95 and 100% ethanol, and allowed to air dry. Slides were then coverslipped using 
Qmount™ Qdot® mounting media (Life-Technologies). 
3.5 WHOLE-SLIDE SCANNING 
Whole Slide Images (WSI) were produced by Dr. Kumiko Isse of the Demitrius 
laboratory and captured via a Zeiss Mirax MIDI scanner utilizing a Plan-Apochromat 
40x/.95N.A. objective lens.  AxioCam MRm digital CCD camera (Carl Zeiss, Jena, Germany) 
and specifically selected excitation/emission Qdot filters (Omega Optical, Brattleboro, VT) as 
previously described(62, 63).  
3.6 IMAGE ANALYSIS 
Pixel-based image analytics were performed on the WSI utilizing the internally 
developed-IAE-NearCYTE (http://nearcyte.org) imaging software developed by Andrew 
Lesniak.  Manual outlining of EMB regions for each sample (See Fig. 2) were completed and 
negative areas (gaps, blood clots, tissue folds) excluded. Following the manual establishment of 
thresholds for fluorophore positivity, the software automatically quantifies the resultant 
fluorophore intensity and total expression area in the defined regions, and the data were exported 
to Microsoft Excel for numeric analysis. 
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3.7 QUANTITATIVE REAL-TIME PCR (qRT)-PCR 
We also evaluated the tissue expression of IL-33 and its membrane-bound receptor ST2 
mRNAs in intestinal allograft biopsies from patients with and without acute rejection by 
quantitative real-time (qRT)-PCR.  Intestinal tissue mRNA expression for IL-33 and ST2 
(among other genes) was measured using a 384 gene Inflammatory Cytokines and Receptors 
gene expression PCR array (Qiagen, Fredericksburg, MD). Fold-Change (2
-ΔΔCT
) was calculated 
as normalized gene expression (2
-ΔCT
) in the Test Sample divided the normalized gene 
expression (2
-ΔCT
) in the Control Sample. The p values were calculated based on a Student’s t-
test of the replicate 2
-ΔΔCT
 values for each gene in the control group and treatment groups. 
3.8 PATHWAY ANALYSIS 
The 384 assessed genes were classified and associated networks were determined by Dr. 
Jeremy Lott, using IPA (Ingenuity© Systems, www.ingenuity.com), with stringency set using 
sample p-values with a cut off value of p≤0.05, up and down regulated genes were considered in 
the analysis using the Ingenuity Knowledge Base.  The upstream regulators of altered genes were 
also analyzed and ranked based on both absolute z-score and p-value as determined by IPA 
software.  
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3.9 STATISTICAL ANALYSIS 
Statistical methods to determine data significance were completed using Prism 5 
(GraphPad Software). Differences between groups were determined using unpaired Student’s t-
tests and Welch's correction when appropriate. Results were considered statistically significant if 
p<0.05.  
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4.0  RESULTS 
4.1 PROOF OF PRINCIPAL STUDIES USING A RODENT HTX MODEL 
To preface our studies in pediatric transplant recipients our group performed a number of 
experiments utilizing a mouse heterotopic transplant model of rejection. Using this approach, we 
published that ST2 increases within allograft heart tissue, an effect not observed in naïve hearts 
or in native heart of the recipients (47). These data indicate that this ST2 increases are most 
likely due to local alloimmune-based inflammation in the graft (47). More recently, using 
Western blot analysis testing lysates generated from allogeneic and syngeneic heart transplants 
excised at day 5 and 10 along with lysates from naïve hearts, we detected a dramatic increase in 
IL-33 in 10-day allograft tissue (Fig. 2A), an observation that had not been previously 
demonstrated in any transplant model. Our group next sought to use Western blot analysis and 
determine which isoform of ST2 is found in the rejecting allograft hearts.  Utilizing an antibody 
that recognizes both ST2 isoforms and relying on differences in molecular weight to distinguish 
the transmembrane form (ST2; ≈60 kDa) from the soluble form (sST2; ≈30 kDa), we confirmed 
that both forms were increased dramatically in allograft hearts (Fig. 2B, top and middle panels). 
Naïve hearts displayed expression of the protein, but not to the degree of the rejecting allografts. 
These data indicate that both IL-33 and ST2 are increased in allografts during rejection.  
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C57BL/6J (B6) or BALB/cByJ hearts were heterotopically transplanted into B6 recipients and were explanted on 
the indicated day post-Tx.  Following tissue disruption, total cellular lysates were probed with an antibody for IL-33 
(R&D). (A) Western blot analysis shows a marginal increase of IL-33 in 5-day and 10-day syngeneic (syn) and 5-
day allogeneic (allo) allograft hearts over naïve B6 hearts. A dramatic increase in IL-33 is observed in 10-day (allo) 
allograft hearts. (B) Western blot analysis for ST2 shows a notable increase in both the transmembrane form of ST2 
(top panel) and in sST2 (middle panel) in day 5 and 10 allo hearts compared to naïve hearts. Following analysis, 
membranes were re-probed with an antibody for GAPDH (Sigma) following stripping, which was used as a loading 
control. 
Figure 2: IL-33 and ST2 are profoundly modulated during rodent heart transplant rejection 
B 
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4.2 AIM 1: DETERMINE IF ST2 AND IL-33 ARE MODULATED LOCALLY IN 
ALLOGRAFT TISSUE BY INFLAMMATORY CYTOKINES 
To establish if expression of ST2 and IL-33 are modulated during clinical heart rejection 
(HTx) as observed in prior murine studies, we investigated IL-33 and ST2 staining patterns in 
EMBs obtained from a cohort of pediatric HTx recipients at the time of diagnosis of AMR 
(donor-specific alloAb
+
 and/or C4d staining) or ACR (ISHLT Grade >2R), as well as in 5 
patients classified as non-rejectors (NoR) that remained free from either ACR or AMR (ISHLT 
0-1R DSA-negative) in the first year following HTx, including the time of EMB 
collection/pathologist evaluation. Patient demographics are highlighted in, Table 5. Following 
Qdot-based multicolor immunostaining of EMBs with antibodies specific for human ST2 and IL-
33, WSI analysis was utilized to quantitate expression levels of each of these molecules which 
enabled identification of target tissue regions and exclusion of areas of obstruction (clots and 
tissue damage). An example of the WSI analytical process is depicted in Fig. 3A. Figure 3B and 
displays a tissue representative of the non-rejecting group (post-operative date (POD) 331 and 
26). In these EMBs there is limited observable expression of ST2 and nuclear IL-33. This is in 
stark contrast to EMBs of patients with ACR (2R ISHLT score; POD 25 & 308; Fig. 3C), which 
exhibit dramatic increases in nuclear IL-33 in endothelial cells of the microvasculature (indicated 
by yellow arrow in Fig. 2C) in addition to an abundance of ST2 in the HTx myocardium. EMBs 
collected from recipients with AMR (Fig. 2D, depicted at POD 11) display similar levels of 
diffuse ST2 staining throughout the myocardium and increased nuclear IL-33. These visual 
observations were reinforced following analysis utilizing the NearCYTE software. 
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A 
C 
B D 
Figure 3: IL-33 and ST2 levels distinguishes pediatric HTx patients suffering rejection  
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(A) Whole slide EMB analysis using NearCyte software as described in the methods.  Multicolor immunostaining 
for IL-33 (Magenta), ST2 (Green) and DAPI (blue) was completed on ISHLT-graded pediatric HTx patient EMB. 
Following staining, slides were scanned with a Mirax MIDI (3D Histech, Budapest, Hungary).  Images were 
generated with the NearCyte program and presented at magnifications of 1, 5, 10, 20, & 40X. (B) Top panels display 
a representative Non-rejecting group (NoR) sample at POD 331 and 26. NoR (n=6) display little IL-33 and confined 
+
areas of ST2 cells. (C) Displays sections of an EMB from a patient undergoing ACR (>3A ISHLT score) POD 305 
and 25. ACR patient EMB (n=4) display distinct modulation of nuclear IL-33 and increased ST2. (D) AMR EMB 
(n=5) showed similar results as ACR (depicted at POD 11). 
Figure 4 depicts the quantitative data derived using the NearCYTE program. The output 
data are presented as florescent area, which is a ratio of number of positive pixels over sum 
measurements of the selected tissue regions. We observed a significant increase in area staining 
positively for both ST2 and nuclear IL-33 (p=0.0359 and 0.0049 respectively) in rejecting EMBs 
compared to those from non-rejecting recipient samples.  These data substantiate the 
observations presented in Figure 3. 
Table 5: Characteristics of Heart Transplant Recipients used in Qdot Analysis 
p-values indicate that is there is no significant difference in age or POD between individuals 
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Tissue analyses were completed as described in Fig 3. Graphs depict calculated Fluorescence Area (microns
2
). At 
points of diagnosed ACR and AMR, levels of ST2 and IL-33 were significantly elevated compared to non-rejecting 
patients (p=0.0359, ST2 & p=0.0049, IL-33) at similar time points post-transplant (A & B). Statistical analysis was 
completed using a Student’s t-test 
To investigate if ST2 and IL-33 levels have relevance to indicate rejection after transplant 
of other organs, we examined IL-33 and ST2 gene expression in small bowel transplant (SBTx) 
recipients.  Specifically, we analyzed IL-33, ST2, along with 382 other immune related genes by 
qRT-PCR in samples from 7 patients at either times of rejection (n=9) or quiescence (n=10).  
Mean ST2 expression exhibited a significant 3.94-fold increase (p=0.0229) in rejection samples 
when compared to controls (Fig. 5A). IL-33 was also increased, however not to a significant 
degree. Thus, examination of biopsy mRNA expression supports distinct modulation of the ST2 
during SBTx rejection. These data, with our above Western Blot data in rejecting rodent HTx or 
quantitative Qdot assessment of HTx EMB, provide further support for increases in local ST2 in 
allograft tissue during rejection episodes. 
Figure 4: Graphical representation of IL-33 and ST2 as measured by Qdot analysis
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In addition to ST2 message, we were able to identify other genes whose expression was 
significantly modulated during SBTx rejection (Table 6).  A total of 36 genes of the 384 assessed 
were modulated significantly during SBTx, 32 increased and 4 decreased when compared to non-
rejection (Table 6 and Fig. 5B). In spite of increased nuclear IL-33 in rejecting HTx samples 
(Fig. 4 and 5), the message for IL-33 was not found significantly modulated (Table 6 and Fig. 
5B).  These data may suggest differences in tissue specific differences in IL-33 regulation. 
Alternatively, modulation of IL-33 mRNA may be a very early change during rejection and not 
evident at the time of diagnosed rejection.  
To further our understanding of the regulation of genes involved in SBTx rejection, these 
qRT-PCR data were probed using IPA pathway and network analysis. This generated associated 
pathways incorporating sets of both upregulated and downregulated genes. Based on fold-
changes and P-values, the top modulated pathway contained ST2 and the representation of the 
gene-gene network is depicted in Fig. 5B. This information was analyzed once again using IPA 
to determine upstream transcriptional regulators that could explain the observed gene expression 
changes.  IPA Upstream Regulator Analytic identified that TNF, LPS, IL-1β, and IFNγ were the 
predicted activators of this network containing ST2 (Table 7).  These data are consistent with 
previous determinations that IL-1β, TNFα, or LPS cause production of sST2 in both cells and 
tissues (59, 64, 65). Likewise, these data indicate that local pro-inflammatory cytokines likely 
mediate the observed increase in allograft ST2 during rejection.  
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Table 6: Up and Down Regulated Genes Comparing Rejection to Control Group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table was generated by IPA software comparing fold regulation between the two groups  
 
 
 
 
Table 5
Up-Down Regulation (comparing rejection to control group)
Expression 
Increased Gene Fold Regulation p-value
1 CSF3 14.7933 0.023996
2 CXCL5 13.2232 0.049074
3 CXCL6 10.4152 0.019259
4 CXCL10 9.3746 0.043514
5 IL1R2 9.3664 0.040937
6 CSF2 8.3832 0.025132
7 SELE 6.3121 0.014821
8 CTLA4 6.113 0.042203
9 MMP9 5.4335 0.020145
10 IFNG 5.237 0.007728
11 MADCAM1 4.9033 0.009603
12 BDKRB1 4.7097 0.00645
13 CD80 4.6207 0.019928
14 PLA2G7 4.2483 0.030589
15 IL1RL1 3.9415 0.022935
16 CCR4 3.8571 0.022242
17 CCL2 3.7402 0.012185
18 ICAM1 3.7257 0.014463
19 PTAFR 3.5569 0.027089
20 TLR8 3.5262 0.013663
21 OAS2 2.9562 0.018015
22 ITGAM 2.7774 0.025266
23 ITGB2 2.6459 0.017446
24 CD86 2.4816 0.035482
25 TNFSF13B 2.4666 0.021849
26 IRAK2 2.3559 0.03155
27 OASL 2.3497 0.032616
28 BDKRB2 2.1952 0.032777
29 ISG15 2.1538 0.043216
30 IFITM1 2.1519 0.021527
31 RIPK2 2.1306 0.044181
32 GBP1 2.104 0.046732
IL33 1.6942 0.755656
Decreased
1 PPARA -2.084 0.026054
2 ACE -3.6617 0.043689
3 IL5 -4.6147 0.021381
4 VIPR1 -7.2288 0.027744
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 Changes in expression of 384 immune-related genes, including IL-33 and ST2, were determined by quantitative RT-
PCR (qRT-PCR) in pathologist scored biopsies from SBTx patients at time points determined to be rejection-free 
(non-rejection; n=14) or undergoing active rejection (n=9).  Presented data represent fold-change 2^
(-ΔΔCT) 
calculated 
as the normalized gene expression 2^
(-ΔΔCT) 
in the Test Sample divided by the normalized gene expression 2^
(-ΔΔCT) 
in 
the Control Sample. The p-values were calculated based on a Student’s t-test of the replicate 2^(-ΔCT) values for each 
gene in the control group and treatment groups. When compared to non-rejections, IL-33 mRNA levels from 
A 
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rejections were not statistically different, however, levels of ST2 mRNA levels were increased in rejections (p=0.02) 
approximately 4-fold when compared to non-rejections (A). (B) To further understand the regulation of genes 
involved in small bowel transplantation rejection, fold-changes and p-values from genes were further analyzed using 
Ingenuity Pathway Analysis (IPA; Ingenuity Systems Software). Upregulated ST2 (IL1RL1) in network of 
significantly modulated genes. Depicted is a graphical representation of the highest-scored network generated from 
our data set and calculated on fold-change and associated p-values.  Level of upregulation is indicated by intensity 
of red color at that node. Gray nodes are part of the network, but were not significantly modified between rejecting 
and non-rejecting samples. Solid lines indicate direct relationships, while dashed lines depicted indirect relationships. 
Figure 5: Tissue expression of ST2 increases in patients undergoing acute rejection of SBTx 
Table 7: TNF and IL-1β Amongst Top 20 Predicted Upstream Activators of ST2 
Table was generated by IPA software, data was derived from activation z-score that determines likely regulators 
based on p-value 
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4.3 AIM 2: DEFINE IF SYSTEMIC ALTERATIONS IN ST2 AND IL-33 ARE 
INDICATIVE OF TRANSPLANT REJECTION 
To determine if both IL-33 and ST2 are identifiable systemically during heart transplant 
rejection we performed ELISA assays on sera collected through routing surveillance of the HTx 
cohort as mentioned in Aim 1. Table 8 summarizes recipient demographics.  We observed that 
serum sST2 significantly increased in pediatric HTx patients at the time of acute rejection (Fig. 
6A) this was in comparison to normal, healthy controls, as well as patients not classified as 
undergoing acute rejection (NoR) (p=0.0011 and p=0.0006). As with sST2 we observed a similar 
significant increase with IL-33 (p=0.0010) (Fig. 6B). These data reinforce the Qdot observations 
in HTx EMBs in Aim 1, indicating that increased ST2 and IL-33 can be found both locally and 
systemically during diagnosed rejection episodes in pediatric HTx recipients.  
 
Table 8: Characteristics of Pediatric Heart Transplant Recipient Samples used for ELISA 
 
 
 
 
 
 
 
 
 
 
 
p-values indicate that is there is no significant difference in age or POD between individuals 
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Serum ST2 and IL-33 levels were assessed by ELISA in pediatric HTx patient sera during post-transplant day 21-50. 
Recipients were group during this period as either “Non-Rejection”  patients, who were free from acute cellular 
rejection (ACR;>2 based on pathologist International Society for Heart and Lung Transplantation [ISHLT] scoring) 
episodes and antibody-mediated rejection (AMR; donor-specific alloAb
+
 and/or C4d staining
+
) or those suffering 
one or more incidence of AMR/ACR during this period. HTx patients suffering ACR or AMR (“ACR/AMR”; n=10) 
displayed significantly increased levels of (A) sST2 and (B)  IL-33 compared to those in the non-rejection group 
(“No Rejection”; n=11)and healthy controls (Normals; n = 9). Indicated significance levels were calculated via 
Prism 5 and a two-tailed, non-paired Student’s  ‘t’ test. 
To determine if local levels of IL-33 and ST2 correlate with systemic levels we compared 
quantitative data from Qdot staining and ELISA analysis derived from EMBs and sera collected 
at the same time-point from several individuals (n=9). We found that with ST2 expression there 
is evidence of correlation between serum levels and tissue expression (Fig. 7A). However, there 
appears to be no real correlation between tissue and serum expression of IL-33 (Fig. 7B). 
Figure 6: Serum sST2 and IL-33 are elevated in pediatric HTx recipients suffering rejection episodes  
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To evaluate if these same results could be translated to rejection in SBTx, we assessed 
levels of IL-33 and sST2 in the sera of pediatric SBTx recipients during quiescence, rejection, or 
enteritis (demographics summarized in Table 9). As we observed in pediatric HTx recipients, 
serum levels of sST2 were significantly increased at the time of pathologist-diagnosed rejection 
(30 incidences) compared to time periods in the same patients when rejection was not evident 
(Non-Rejection; 24 incidences; Fig. 7A). Levels of IL-33, however, do not appear to be 
significantly altered during rejection compared to periods of non-rejection (Fig 7B). 
Significantly, increases in sST2 (p=0.0306) (Fig. 7A) appear to be specific to rejection and 
differentiated from non-specific enteritis (p=0.0046) (11 incidences) in SBTx patients (Fig. 7). In 
all, these data demonstrate that serum sST2 is elevated during allograft rejection in pediatric 
SBTx recipients and thus provide further evidence to support systemic sST2 as a biomarker of 
allograft rejection. 
A B 
Expression of ST2 shows some correlation between high and low levels in the tissue and serum (A), however, tissue and 
serum levels of IL-33 do not seem to demonstrate this same trend. 
Figure 7: Co rrelative analyses of tissue and serum expression of ST2 and IL-33
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Table 9: Characteristics of Pediatric Small Bowel Transplant Recipients used for ELISA 
(A-B) The level of circulating (A) sST2 and (B) IL-33 was assessed by ELISA in SBTx patient serum as above. 
Patient samples (n=15) were assessed at times of diagnosed rejection (25 incidences) and display significantly 
increased levels of sST2 compared to periods of non-rejection (n=18), patients diagnosed with enteritis (n=12), and 
donor serum samples (n=4). (B) IL-33 does not show a significant difference between non-rejection, enteritis, and 
rejecting patients. Indicated significance was calculated via Prism 5 and a two-tailed Student’s  ‘t’ test. 
Figure 8: Serum sST2 is elevated in pediatric SBTx recipients during diagnosed rejection episodes 
Table  5 .  Characteristics of Pediatric Small Bowel Transplant Recipient Samples Used for ELISA
n= Males Age at Tx ±STD POD ±STD
No rejection (NR) n=16; 27 incidences 38% 9.15 10.69 205.9 300.0
Rejection ( R) n=13; 29 incidences 38% 6.53 9.10 591.3 281.6
Non-specific enteritis (NE) n=10; 11 incidences 30% 4.82 6.15 335.5 392.0
P= NR vs R 0.62 1E-05 *
NR vs. NE 0.37 0.369
R vs NE 0.71 0.29
p-values indicate that there are significant differences in age or POD between individuals within groupings 
due to data collected overtime from the same patients 
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5.0  DISCUSSION 
To date the most significant advancements in post-transplant survival have occurred 
within the first year, due largely to the development of effective immunosuppressant therapies 
(12).While survival after the first year has been steadily improving within the last 10-20 years, it 
still follows a downward trend (10, 12). Complications suffered by long term survivors such as 
malignancy, infection, cardiac allograft vasculopathy (CAV), and renal toxicity, are directly or 
indirectly related to IST (10). Patients experiencing these complications often require reduced 
IST, which can precipitate into rejection episodes (22). Monitoring of rejection typically involves 
a pathologist-graded biopsy and patients who have or are at high risk of rejection often times 
require several of these a year. This procedure is painful, expensive, and can in itself cause organ 
dysfunction (14). Even with multiple samples taken per biopsy procedure, there is still limited 
tissue area available for analysis, which can lead to inaccurate diagnoses. These issues indicate a 
need for improved non-invasive rejection surveillance. Identification of a sensitive biomarker of 
early rejection would post-transplant care. 
In this study, we have made several novel findings that strongly support the assessment 
of ST2 and IL-33 as means to aid diagnosis of pediatric transplant rejection.  In both pediatric 
HTx and SBTx we reveal that quantifiable modulations of ST2 take place in the allograft during 
episodes of rejection. To the best of our knowledge, this represents the first demonstration of 
increased ST2 in rejecting clinical allograft samples. We also demonstrate that increased levels 
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of circulating sST2 occur at times of diagnosed rejection in HTx recipients. These findings are 
consistent with a recent report completed in a case-crossover study of sST2 levels in sera of adult 
HTx recipients (41). To expand on our findings in HTx recipients, we examined sera from 
pediatric SBTx recipients and found comparable increases in sST2. These data represent the first 
assessment of ST2 modulation following SBTx and support our original theory that serum 
increases in ST2 can be induced in association with inflammation caused by alloimmune 
responses, not only as a result of heart damage and myocardial stress as currently believed (49).  
In addition to our findings in regards to ST2 expression in pediatric transplant recipients, 
we also acquired novel evidence of upregulation of the cytokine IL-33 in correlation with 
allograft rejection. IL-33 is associated with several inflammatory driven conditions. However, its 
presence during rejection has until now been unexplored. As with ST2, we identified increased 
nuclear IL-33 in rejecting tissues of HTx recipients as well as in the serum. In the case of SBTx, 
levels of IL-33 were less informative and appeared to be non-specific in differentiating between 
rejection and quiescent periods. This may be an inherent characteristic unique to the signature of 
small bowel transplants due to the complicated environment of the gut or evoked by increased 
inflammation and tissue trauma created by the surgery itself resulting in the release of IL-33 as 
an alarmin.  Nevertheless, further examination is required to assess how IL-33 is modulated 
during SBTx. 
Our recent observations support the concept that increases in systemic sST2 are driven by 
inflammatory events and are not unique to cardiovascular pathology.  Likewise, they provide 
evidence that during inflammatory diseases, including graft-versus-host disease (GVHD), 
inflammatory bowel disease, ulcerative colitis, sepsis, arthritis, and now transplant rejection, 
circulating ST2 is associated with disease pathology. Further supporting this theory is that 
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increased ST2 observed during ulcerative colitis is decreased when patients are administered 
anti-TNF therapy (43, 44, 46).   
Qdot-based, multicolor immunostaining of pediatric heart transplant EMBs revealed that 
expression of ST2 is minimally expressed in quiescent HTx biopsies, but is profoundly increased 
in the myocardium during ACR and AMR.  This reinforces our previous observation that ST2 
protein is upregulated in rejecting heterotopic murine HTx, but not endogenous recipient hearts 
(47). Levels of IL-33 were also increased in both groups of rejecting patients with similarly low 
expression in EMBs of patients not actively rejecting. Analysis of gene expression in biopsies of 
SBTx recipients revealed an analogous upregulation of ST2 mRNA in samples acquired during a 
period of rejection. ST2 was also determined to be amongst the most dominantly modulated gene 
networks and its activity is most likely regulated upstream by TNFα, LPS, IL-1β, and IFNγ.  
Although our study has yielded many significant findings, it is not without limitations. 
One limitation was the inability of our biopsy-based Qdot assessments to distinguish between 
ST2 and sST2, due to utilization of probes recognizing shared regions of both. However, 
Western blot analysis performed during preliminary examinations using a model of murine HTx 
demonstrate that the increased levels of both isoforms of ST2 in the allograft during rejection. 
Moving forward it will be important to substantiate these rodent observations before regarding 
the allograft as a possible source of sST2 either by developing Qdot probes specific for the 
secreted isoform or similarly developing qRT-PCR primers that recognize isoform specific 
sequences.  
Another issue centers around the limited sample size in both our HTx and SBTx cohorts.  
Since these are both relatively rare procedures, particularly in children, the availability of 
pediatric samples is limited, which forced us out of necessity to use a retrospective study design. 
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Likewise, in our examination of HTx recipients, limited serum samples and biopsies were 
available for assessment, resulting in small sample sizes for both ACR and AMR time points 20-
100 POD. Thus, in our Qdot analyses of patient EMBs we chose to assess the groups together in 
a single “rejection” cohort. Even though both ACR and AMR are representative of alloimmune-
mediated graft damage, we do appreciate that they are distinct forms of rejection with distinct 
characteristics. Nevertheless, the principal goal of our study was to establish if rejection, either 
ACR or AMR, is able to modulate expression of IL-33 or ST2, either locally in allograft tissue or 
systemically in the sera of pediatric Tx recipients. Likewise, the emergence of pro-inflammatory 
cytokines expected to drive ST2 and IL-33 is shared between both ACR and AMR. When ELISA 
data are assessed individually, both the ACR (n=6; 8 incidences) and AMR (n=4; 4 incidences) 
cohorts display a significantly increased level of circulating sST2 and IL-33 (p≤0.05; Unpaired 
Student t test) at POD 20-100 relative to quiescent patients during this timeframe (n=11; 14 
incidences).  This is in comparison to analysis of individual groups using Qdot analysis, in which 
each group only displays a trend towards increased ST2 and IL-33 expression (p≥0.05). To build 
on our data derived from both tissue and serum analysis, we wanted to determine if local and 
systemic expression of ST2/IL-33 correlate within a patient at a single time point. Once again, 
due to our limited sample size we were restricted to only a small number of patients who had 
both biopsies and serum collected on the same date available for study. Even so, we were able to 
see a trend where graft ST2 correlated with serum ST2 levels. IL-33 did not correlate between 
serum and tissue. This may suggest that distinct pathways for release of ST2 and IL-33 exist.  
Specifically, sST2 in the serum is expected to be secreted rapidly after induced by pro-
inflammatory cytokines.  Alternatively, IL-33, while increased in the graft may not become 
evident in the sera until released during tissue damage.  
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We encountered another limitation when assessing our SBTx studies.  Due to the absence 
of rejection-free SBTx recipients and limited availability of control or donor tissue, we were 
required to compare episodes of rejection, quiescence, or diagnosed enteritis within the same 
patient. While this situation may have created difficulty in assessment of rejection vs. a true 
rejection free environment, it did provide us with a unique opportunity. It enabled us to gain 
insight into chronological changes in circulating sST2, and to a lesser degree IL-33, relative to 
quiescence, diagnosis of rejection, and start of rejection treatment.  Similar to HTx data findings 
reported by by Pascual-Figal et al. (49), we also observed in our cohort of SBTx patients that 7 
of 12 SBTx recipients assessed for circulating sST2 had a ≈2-fold or greater increase during 
emergence of initial rejection episode when compared to prior serum samples taken during 
quiescence (Fig. 9, supplementary data; Average fold change = 12.24±15.79; Max = 43.63; 
Min= 0.15).  Likewise, rejection treatment tended to result in a decrease in sST2 levels (Fig. 9, 
supplementary data). While encouraging, these observations are complicated by the fact that 
sST2 levels were profoundly decreased even when rejection treatment was unsuccessful and 
resulted in loss of the allograft (n=3) (Fig. 9, supplementary data).  Thus, while our data reveal 
that sST2 increases are associated with initialization of rejection episodes, further research in 
SBTx is necessary to define if differences in sST2 levels are acting as an indicator of successful 
rejection treatment or resulting from loss of sST2 producing cells during severe rejection.  
Overall, we have completed the first simultaneous biopsy and serum based assessment of 
ST2 and IL-33 in two distinct pediatric transplant populations.  We establish that both molecules 
are easily quantifiable in samples taken during routine surveillance protocols and increase 
significantly during episodes of rejection. Despite our sample constrains, our data examining 
circulating levels of sST2 and IL-33, as well assessing tissue expression of these proteins in both 
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patient EMBs and in murine allograft heart, in total make a convincing case for potential use of a 
combination biopsy/serum based assay of ST2 and IL-33 to assess rejection. Our study lays the 
groundwork for future verification of ST2 and IL-33 as robust biomarkers of rejection. This 
discovery would help to lessen the burden of IST related complications by allowing doctors to 
maintain recipients at a lower level of IST given that they could rapidly detect early rejection and 
address before damage to graft results. This targeted adjustment of IST regimen would decrease 
accumulative IST side effects over time. Reliable biomarkers would also revolutionize transplant 
diagnostic procedures, enabling a less invasive approach to rejection diagnosis. Both 
improvements would lead to better adherence to treatment and screening protocols. In time, this 
should improve graft attrition rates and long-term patient survival to the benefit of public health. 
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6.0  FINAL SUMMARY 
Our study findings are summarized in a diagram below (Fig. 9). Given our IPA data 
suggesting that TNF, IL-1, and IFN are the dominant drivers of ST2 during rejection, we 
believe that the inflammatory cytokines generated by graft-infiltrating immune cells during ACR 
and AMR trigger upregulation of ST2 and sST2 in cardiac myocytes and fibroblasts. These 
cytokines include IFNγ from infiltrating activated T-cells and TNFα and IL-1β from 
inflammatory macrophages.  Accordingly, sST2 would be released into the circulation and ST2 
would be readily detectable during early AMR and ACR. Our Qdot data demonstrates nuclear 
expression of IL-33 is also upregulated at this time, however we anticipate that release of IL-33 
will result from tissue damage. Thus, we believe sST2 would be most useful as a biomarker for 
early rejection and unlike previously tested biomarkers which are indicators primarily of 
necrosis, we expect sST2 to be measurable before significant damage has occurred. As for IL-33, 
we propose that it could serve as a tissue biomarker, detectable by biopsy early in rejection, 
however, it presence in the serum suggests that it is being released most likely due to tissue 
damage or necrosis. This suggests that IL-33 may be an effective marker of advanced rejection 
and could be included in a panel with other markers of necrosis such as cardiac troponin I and 
creatine kinase.  
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Figure 9: Schematic representation of increased IL-33 and ST2/sST2 expression and release during 
allograft rejection (ACR/AMR)
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Inflammatory cytokines are generated during ACR and AMR by infiltrating mononuclear cells 
(macrophages/T-cells) within the allograft (1). These cytokines induce upregulation of ST2, 
sST2, and IL-33 in cardiac myocytes and fibroblasts (2). Secretion of sST2 is triggered which 
allows for quantitation of this molecule in the serum (3). Advanced rejection can result in tissue 
damage/necrosis, which can be mediated by targeted lysis of cells by activated macrophages and 
cytotoxic T-cells due to granzyme/perforin activity (4). IL-33 along with other markers of 
necrosis such as cardiac troponin I and creatine kinase are subsequently released into the serum 
as a result of this damage (5), thus indicating that IL-33 may be more useful as a marker of 
necrosis rather than for rejection.  
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7.0  FUTURE DIRECTIONS 
The limitations within our study highlight the necessity of additional research in order to 
further reinforce our conclusions. Expanding our HTx population, especially in the AMR group, 
would add to the impact of our current findings. Currently our Qdot analyses only display a trend 
towards increased IL-33 and ST2 in AMR. We expect that by adding additional patient samples 
to this group, observed differences will reach statistical significance. Also, growing this 
population would also enable us to examine a wider range of time points which would allow us 
to observe if POD plays a role in appearance of these markers in relation to time of rejection 
diagnosis to start of treatment and rejection resolution. For example, in a perfect scenario we 
would expect to observe a measurable increase in sST2/IL-33 prior to diagnosis of rejection, 
similarly high levels in both tissue and serum at time of rejection, and a subsequent decrease in 
IL-33 and ST2 post successful treatment and resolution of rejection. In addition, we would also 
like to build on our tissue/serum correlative studies in order to see a solid relationship between 
circulating levels of IL-33 and sST2 and tissue levels of the molecules. Due to the unsuccessful 
Qdot staining resulting from the poor condition of the small bowel biopsies that we received 
from our collaborators in Nebraska, we lacked a Qdot assessment for this population. In the 
future, we are anticipating receipt of chronologically obtained SBTx biopsies from Children’s 
Hospital of Pittsburgh, which should allow us to complete Qdot-based staining and provide a 
basis of comparison with our HTx study findings. 
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Also, given that infections, particularly viral, are common in immunosuppressed 
transplant recipients, it is essential that a biomarker of rejection be exclusive to rejection and not 
influenced by inflammatory markers induced by viral infections. Inflammatory cytokines such as 
IL-6, IL-12, TNFα, and IFNγ, identified during episodes of PTLD which is driven by EBV, have 
also been detected in rejecting patients, making them poor candidates as biomarkers. In our 
study, we found in SBTx assessments that levels of sST2 and IL-33 were significantly higher at 
time of rejection than during diagnosed enteritis, which can have several causes including viral 
infection (66). This suggests that elevated measurements of ST2 and IL-33 are unique to 
rejection. However, further assessment will be necessary to determine if this is in fact the case. 
To expand on this observation we plan to assess IL-33/sST2 along with a panel of other 
inflammatory cytokines in the sera of pediatric HTx recipients who will be grouped based on 
EBV status, which is determined through routine surveillance, along with rejection status. 
Through these studies we hope to gain knowledge of how expression of these molecules is 
modulated in a rejection/infection system. 
 
48 
APPENDIX: SUPPLEMENTARY DATA 
Red arrows represent times of severe rejection, while black arrows indicated time points of mild to moderate 
rejection.  Open circles represent incidence of enteritis and X indicate loss of graft.   Black dashed line depicts 
normal levels observed in donor serum + 2SD.   Purple dashed lines indicate manually connected time-points were 
no serum samples were available for evaluation. POD = post-operative day. 
Figure 10: Changes over time in serum levels of sST2 in three representative SBTx recipients 
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